Remix Therapeutics to Present Preclinical Data Demonstrating MYB mRNA Degradation in AML at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

ON December 7, 2023 Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to modulate RNA processing and address underlying drivers of disease, reported an upcoming presentation introducing REM-422, the Company’s potent, selective, oral small molecule messenger RNA (mRNA) degrader, as a potential treatment for MYB-driven cancers (Press release, Remix Therapeutics, DEC 7, 2023, View Source [SID1234638270]). Data describing the activity of REM-422 in AML xenograft models will be highlighted at the 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (ASH) (Free ASH Whitepaper), taking place from December 9-12, 2023 in San Diego. Results demonstrate oral dosing of REM-422 degrades MYB mRNA, inducing anti-leukemic activity in multiple xenograft models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These compelling data support the therapeutic rationale of targeting MYB with REM-422 as a potential treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix Therapeutics. "REM-422 is the first compound entering the clinic from the REMaster discovery platform and we look forward to the start of clinical development in patients with MYB-dysregulated malignancies."

Lead author Charles Kung, PhD, Vice President of Biology, concludes "MYB is an important oncogenic transcription factor that is dysregulated in the majority of AML and MDS patients and we look forward to bringing REM-422 to patients in need of new treatment options."

Details for the poster presentation are as follows:

Title: REM-422, a potent, selective, oral small molecule mRNA degrader of the MYB oncogene, demonstrates anti-tumor activity in mouse xenograft models of AML
Abstract Number: 1425
Session Name: Poster Session I – Presentations
Session Date and Time: Saturday, December 9, 2023, 5:30 PM-7:30 PM
Session Location: Poster Hall